Implications for Healthcare Under the Trump Administration
It's been a change filled month since President Trump took office. Many are still wondering what changes are still to come. Here we address three common questions healthcare providers have.
By Jenny Hamrick
In the wake of a new administration, Americans — along with many healthcare professionals — are asking one big question: What’s going to happen to healthcare with Trump? Some healthcare leaders have high hopes for Trump’s new era, from decreased regulations to changes in the ACA. Regardless of your position, these three questions remain at the forefront for every clinician and healthcare leader.
1. What will happen to the Affordable Care Act?
According to a recent survey of healthcare leaders, most healthcare leaders prefer changes to ACA, as opposed to Trump’s proposed repeal and replace model. Changing the current model could reduce implementation costs, while not disrupting complex infrastructure that has already been established. Although there remain concerns regarding Trump’s upheaval of the ACA, it is incredibly unlikely that there are grounds to repeal the entire act.
2. Will we continue to transition to value-based care models?
There have been many questions about Trump’s position on adopting a value-based payment model. “Democrats and Republicans alike have indeed recognized the need to lower costs and improve the quality of healthcare delivery,” says Elizabeth Whitman, a reporter for Modern Healthcare magazine. “Efforts to move away from fee-for-service to value-based care are also enshrined in places besides the Affordable Care Act,” adds Whitman, places that provide ample opportunity for continued movement towards value-based models of care regardless of changes to the ACA.
3. What about deregulation?
Maybe most interesting to clinicians and Americans together is the rise in conversations regarding deregulation, particularly focused on drug prices. Early in his race, President Trump made it clear that he thinks drug prices are too high, but stripping the prohibition that bans federal government from negotiating directly with pharmaceutical companies for drugs that Medicare covers could have significant economic concerns. “I worry that if you force price across the market, you may well end up with a higher price in noncompetitive categories than you would otherwise,” states Dan Mendelson, president of Avalere Health. Conversations surrounding regulation will continue to present new questions for clinicians and the healthcare community at large.
While many of Trump’s policies are yet to be seen, it is clear that the clinical community is divided on the best course of action. “66% of healthcare providers remain divided on the best approach forward,” says Jonathan Bees, senior research analyst at HealthLeaders Media. Questions about the ACA, value-based care models and deregulation will continue to be an important conversation for the new administration in the coming years.
While the future of the ACA may be in question, your future in healthcare doesn’t have to be. Learn how Relode is changing healthcare hiring, and as a result, healthcare as a whole for the better.